Cerus (NASDAQ:CERS) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

Shares of Cerus Corporation (NASDAQ:CERS) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.69 and traded as high as $2.43. Cerus shares last traded at $2.34, with a volume of 904,537 shares.

Analysts Set New Price Targets

CERS has been the topic of a number of analyst reports. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a report on Monday, January 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cerus in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.00.

Cerus Stock Performance

The company has a quick ratio of 1.29, a current ratio of 1.89 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $449.49 million, a price-to-earnings ratio of -29.25 and a beta of 1.52. The stock’s 50-day simple moving average is $2.18 and its 200 day simple moving average is $1.69.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.02. The company had revenue of $60.24 million during the quarter, compared to analysts’ expectations of $55.12 million. Cerus had a negative net margin of 8.01% and a negative return on equity of 27.58%. Analysts expect that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Cerus

A number of hedge funds and other institutional investors have recently made changes to their positions in CERS. UBS Group AG raised its holdings in shares of Cerus by 227.1% in the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company’s stock valued at $2,354,000 after buying an additional 793,244 shares during the last quarter. Round Rock Advisors LLC acquired a new stake in Cerus in the 4th quarter valued at about $545,000. CWM LLC raised its stake in shares of Cerus by 6.8% in the fourth quarter. CWM LLC now owns 129,084 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 8,178 shares during the last quarter. Bingham Private Wealth LLC acquired a new position in shares of Cerus during the fourth quarter worth approximately $40,000. Finally, SG Americas Securities LLC lifted its position in shares of Cerus by 52.9% during the fourth quarter. SG Americas Securities LLC now owns 61,268 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 21,206 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.